Showing results (51-60 of 552) with videos related to

Sort By:
Pageof 56
Current Opinion in Microbiology|April 6, 2002
Bacterial cell-to-cell communication: sorry, can't talk now - gone to lunch!Klaus Winzer, Kim R Hardie, Paul Williams
International Journal of Molecular Sciences|September 16, 2017
Investigation of Antimicrobial Peptide Genes Associated with Fungus and Insect Resistance in MaizeJoseph Noonan, William Paul Williams, Xueyan Shan
Canadian Journal on Aging = La Revue Canadienne Du Vieillissement|May 1, 2014
Balancing formal and informal care for older persons: how case managers respondAllie Peckham, A Paul Williams, Sheila Neysmith
Acute Cardiac Care|October 29, 2013
Acute myocardial infarction due to coronary artery embolus associated with atrial fibrillationBo Xu, Paul Williams, Andrew T Burns
Methodsx|December 1, 2022
MatGel: A MATLAB program for quantitative analysis of 2D polyacrylamide electrophoresis (2D-PAGE) protein gel imagesAlka Tiwari, W Paul Williams, Xueyan Shan
Bulletin of Mathematical Biology|November 24, 2011
Cross-strain quorum sensing inhibition by Staphylococcus aureus. Part 2: A spatially inhomogeneous modelSara Jabbari, John R King, Paul Williams
Mathematical Biosciences|March 11, 2010
A mathematical investigation of the effects of inhibitor therapy on three putative phosphorylation cascades governing the two-component system of the agr operonSara Jabbari, John R King, Paul Williams
CNS Drugs|December 28, 2006
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraineDavid W Dodick, Giorgio Sandrini, Paul Williams
Bulletin of Mathematical Biology|November 24, 2011
Cross-strain quorum sensing inhibition by Staphylococcus aureus. Part 1: A spatially homogeneous modelSara Jabbari, John R King, Paul Williams
Arthritis and Rheumatism|September 29, 2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsRoy Fleischmann, Maurizio Cutolo, Mark C Genovese, et al.
Pageof 56